A Study to Analyze The Impact of Pharmacist Consultation in Patients Beginning Intravenous Cancer Treatment


About this study

The purpose of this study is to assess the impact of pharmacist consultation in patients receiving first dose, first cycle intravenous cancer treatment on patient understanding of the cancer treatment, adverse drug events, and adherence. Additionally, this study will report the frequency of healthcare utilization for side effect management.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • ≥ 18 years of age.
  • Patients receiving first dose, first cycle cancer treatment within the clinic.
  • Receiving treatment for cancer within the Mayo Clinic Health System in Wisconsin at Barron, Eau Claire, La Crosse, or Menomonie, Wisconsin.
  • Patient must be naïve to injectable chemotherapy.
  • Accepting intervention with oral consent.

Exclusion Criteria:

  • < 18 years of age.
  • Patients receiving non first cycle cancer treatment.
  • Refusal of pharmacist consultation.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

La Crosse, Wis.

Mayo Clinic principal investigator

Travis Dash, Pharm.D., R.Ph.

Closed for enrollment

More information


Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions